Fitfile Secures £2.1m Series A to Scale Privacy-Preserving Health Data Platform

London-based health data technology company Fitfile Group Limited has raised £2.1m in a Series A funding round, achieving a post-money valuation of £6.2m. The allotment date for the round was 31 December 2025, with the filing completed today, 16 March 2026.

Founded in March 2020 by Philip Russmeyer, Fitfile addresses the persistent challenge of siloed medical and consumer records in the healthcare and life sciences sectors. The company provides a privacy-preserving data linkage and analytics platform that enables the secure integration of these complex datasets. Its technology allows organisations to generate real-time population health insights and identify specific patient cohorts without moving or exposing sensitive personal identifiers.

By keeping data at its source and utilising federated computation, Fitfile ensures compliance with strict data protection regulations while unlocking the value of real-world health data for research, planning, and patient care. The platform is already being utilised to resolve data silos across key therapeutic areas, with the company having engaged with major UK healthcare providers including St George's University Hospitals, Barts Health, and King's College Hospital.

The company currently operates with a lean team, reporting nine employees in its latest corporate accounts and 16 on its LinkedIn profile. Financial metrics such as revenue and profit or loss have not been publicly disclosed.

The £2.1m Series A round marks a significant financial milestone for Fitfile, which has largely operated without disclosed institutional funding since its inception. The £6.2m post-money valuation reflects the proprietary infrastructure the company has built over the past six years. Specific investors participating in this Series A round remain undisclosed.

This capital injection arrives at a transitional moment for the UK healthtech and life sciences funding landscape. Following a challenging period in 2025, which saw a 13.2% year-on-year drop in UK biotech and healthtech venture capital investment to approximately £1.8bn, the market is demonstrating renewed momentum in 2026. Industry reports indicate that the final quarter of 2025 saw the highest quarterly deal count of the year, signalling a recovery driven by investors seeking disciplined, highly validated technologies.

Venture capital is increasingly flowing toward infrastructure that integrates deeply into healthcare workflows and enables advanced analytics. Fitfile's focus on secure data unification positions it squarely within this demand, as healthcare providers and pharmaceutical companies look for safe, compliant ways to leverage fragmented data for targeted drug development and improved clinical outcomes.